If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX(1-800-545-5979)
Rezvoglar™ (insulin glargine-aglr) injection
3 mL (100 units/mL)This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What is the indication for Rezvoglar™ (insulin glargine-aglr)?
Rezvoglar is indicated to improve glycemic control in patients with diabetes.
US_cFAQ_REZ011_INDICATION
en-US
Indication for Rezvoglar
Rezvoglar™ (insulin glargine-aglr) 100 units/mL is a long-acting human insulin analog indicated to improve glycemic control in
- adults and pediatric patients with type 1 diabetes, and
- adults with type 2 diabetes.1
Rezvoglar is not recommended for the treatment of diabetic ketoacidosis.1
Enclosed Prescribing Information
Reference
1Rezvoglar [package insert]. Indianapolis, IN: Eli Lilly and Company; 2021.
Date of Last Review: February 02, 2022
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon – Friday, 9am-7pm (EST), excluding holidays